Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties

Open access

Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties

The potential of liquisolid systems to improve the dissolution properties of a water-insoluble agent (indomethacin) was investigated. In this study, different formulations of liquisolid tablets using different co-solvents (non-volatile solvents) were prepared and the effect of aging on the dissolution behaviour of indomethacin liquisolid compacts was investigated. To evaluate any interaction between indomethacin and the other components in liquisolid formulations, X-ray powder diffraction (XPD) and differential scanning calorimetry (DSC) were used. Dissolution test was carried out at two different pH, 1.2 and 7.2, to simulate the stomach or intestine fluid, respectively. The results showed that liquisolid formulations exhibited significantly higher drug dissolution rates at pH 1.2 and 7.2 compared to compacts prepared by the direct compression technique. The enhanced rate of indomethacin dissolution from liquisolid tablets was probably due to an increase in wetting properties and surface area of drug particles available for dissolution. In order to investigate the effect of aging on the hardness and dissolution rate of liquisolid compacts, the formulations were stored at 25 °C/75% relative humidity for a period of 12 months. The results showed that aging had no significant effect on dissolution profiles of liquisolid tablets. Liquisolid compacts containing propylene glycol as vehicle produced higher dissolution rates in comparison with liquisolid compacts containing PEG 400 or Tween 80 of the same concentration. The DSC and XPD results showed no changes in crystallinity of the drug and interaction between indomethacin and excipients (Avicel and silica) during the process.

References
  • S. G. Kapsi and J. W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229 (2001) 193-203.

  • A. J. Aguiar, A. J. Zelmer and A. W. Kinkel, Deagglomeration behavior of relatively insoluble benzoic acid and its sodium salt, J. Pharm. Sci. 56 (1967) 1243-1252.

  • P. Finholt and S. Solvang, Dissolution kinetics of drugs in human gastric juice; the role of surface tension, J. Pharm. Sci. 57 (1968) 1322-1326.

  • S. L. Lin, J. Menig and L. Lachman, Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water insoluble drugs, J. Pharm. Sci. 57 (1968) 2143-2146.

  • S. Spireas and S. Sadu, Enhancement of prednisolone dissolution properties using liquisolid compacts, Int. J. Pharm. 166 (1998) 177-188.

  • S. Spireas, S. Sadu and R. Grover, In vitro release evaluation of hydrocortisone liquisolid tablets, J. Pharm. Sci. 87 (1998) 867-872.

  • S. Spireas, T. Wang and R. Grover, Effect of powder substrate on the dissolution properties of methchrothiazide liquisolid compacts, Drug Dev. Ind. Pharm. 25 (1999) 163-168.

  • K. Y. Yang, R. Glemza and C. I. Jarowski, Effect of amorphous silicon dioxide on drug dissolution, J. Pharm. Sci. 68 (1979) 560-565.

  • C. Liao and C. I. Jarowski, Dissolution rates of corticoid solutions dispersed on silicas, J. Pharm. Sci. 73 (1984) 401-403.

  • A. Nokhodchi, Y. Javadzadeh, M. R. Siahi and M. Barzegar-Jalali, The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts, J. Pharm. Pharm. Sci. 8 (2005) 18-25.

  • United States Pharmacopocia 26, Natural Formulary 21, USP Convention, Rockville 2003.

  • P. Costa, An alternative method to the evaluation of similarity factor in dissolution testing, Int. J. Pharm. 220 (2001) 77-83.

  • P. Costa and J. M. S. Lobo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133.

  • K. A. Khan, Concept of dissolution efficiency,J. Pharm. Pharmacol. 27 (1975) 48-49.

  • H. Abdou, Effect of the physicochemical properties of the drug on dissolution in Dissolution, Bioavailability and Bioequivalence (Ed. H. Abdou), Edison Mack Publishing Co., Easton, PA 1989, pp. 53-72.

  • N. Kaneniwa, M. Otsuka and T. Hayashi, Physicochemical characterization of indomethacin polymorphs and transformation kinetics in ethanol, Chem. Pharm. Bull. 33 (1985) 3447-3455.

  • H. Imaizumi, N. Nambu and T. Nagai, Stability of several physical properties of amorphous and crystalline forms of indomethacin, Chem. Pharm. Bull. 28 (1980) 2565-2569.

  • L. Borka, Polymorphism of indomethacin. New modifications, their melting behavior and solubility, Acta Pharm. Suecica 11 (1974) 295-303.

  • M. Otsuka, F. Kato and Y. Matsuda, Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry, Analyst 126 (2001) 1578-1582.

  • M. Yoshioka, B.C. Hancock and G. Zografi, Crystallization of indomethacin from the amorphous state below and above its glass transition temperature, J. Pharm. Sci. 83 (1994) 1700-1705.

  • H. Imaizumi, N. Nambu and T. Nagai, Stabilization of amorphous state of indomethacin by solid dispersions in polyvinylpyrolidone, Chem. Pharm. Bull. 31 (1983) 2510-2512.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 42 42 30
PDF Downloads 12 12 10